Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis

Abstract

Purpose To investigate the efficacy and safety of programmed cell death 1 (PD-1)/programmed cell deathligand 1 (PD-L1) plus cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies ± other therapies in patients with advanced lung cancer. Methods In accordance with the retrieval strategy, we searched electronic databases for randomised controlled trials testing PD-1/PD-L1 plus CTLA-4 antibodies in patients with lung cancer; RR (for objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs)) from individual studies were calculated and pooled by using random-effects models or fixed-effects models; heterogeneity and publication bias analyses were also performed, using Review Manager 5.3 and Stata 15.1 for statistical analysis. Results We included six studies. Four different immune checkpoint inhibitors (nivolumab, pembrolizumab, durvalumab, tremelimumab) were used. Dual checkpoint inhibitors ± other therapies for advanced lung cancer showed significant improvements in ORR (RR 1.49, 95% CI 1.11 to 1.98; p=0.007), OS (HR 0.72, 95% CI 0.63 to 0.83; p<0.00001), and PFS (HR 0.72, 95% CI 0.63 to 0.82; p<0.00001). The subgroup analyses were consistent with the pooled results. The PD-L1 ≥1% (HR 0.67, 95% CI 0.54 to 0.82; p<0.0001) subgroup differences indicated a statistically significant subgroup effect, but the PD-L1 <1% subgroup (HR 0.88, 95% CI 0.75 to 1.05; p=0.15) was not statistically significant. The incidence of adverse events (grade ≥3) was lower than that of the control group (RR 0.90, 95% CI 0.80 to 1.02; p=0.09), but was not significant. Conclusions PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors ± other therapies can improve the ORR, OS and PFS of patients with advanced or metastatic lung cancer, but the incidence of adverse reactions is high although generally tolerable.

Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications

“…Dual immunotherapy has exhibited durable benefits in OS and PFS regardless of PD-L1 expression compared to chemotherapy ( 24 , 25 ). Combined immunotherapy or dual immunotherapy might also increase adverse effects (AE) ( 26 ).…”

Trends in the use of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020, a national cancer registry analysis

“…Previous evidence provided by RCTs has shown bene cial effects in the clinical outcomes of lung cancer patients treated with ICIs, such as increased OS and more favorable treatment response [9][10] [11]. The main survival results from our study are, depending on the speci c ICI prescribed, comparable to the ones provided by previous relevant RCTs evaluating the use of ICIs as rst-line for NSCLC treatment; nding a median OS of 17.4 months in the NCR, compared to a range between 17.1-23.2 months in RCTs.…”

Autophagy and Glycometabolic Reprograming in the Malignant Progression of Lung Cancer: A Review

“…However, patients with lung cancer still face problems such as drug resistance, metastasis, and recurrence. 79 Malignant progression of cancer is closely correlated with the abnormal upregulation of autophagy and glycometabolic reprograming in lung cancer cells. The effects of autophagy on glycolysis and the transcription or expression levels of key enzymes are also potentially important in influencing cancer development and progression.…”